Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
In a study to be presented at the CTS-IXA Congress today, Lorenzo Piemonti, M.D., the director of the islet transplantation program at the San Raffaele Diabetes Research Institute of Milan, will show Phase II clinical data that supports the development of Reparixin for use in pancreatic islet transplantation experimental procedure as an alternative to pancreas transplant in patients with advanced stages of Type 1 diabetes who develop a resistance to insulin.
These patients often face frequent hypo- and hyper-glycemic crisis with the risk of serious consequences, particularly to the kidneys. In such cases, pancreas transplant has been the standard procedure, but recently, due to efforts of the transnational scientific community, pancreatic islet transplantation has progressively been affirmed as a potential alternative procedure and new frontier in the treatment of Type 1 diabetes.
http://www.sacbee.com/2011/10/24/4003270/new-frontier-in-the-treatment.html
These patients often face frequent hypo- and hyper-glycemic crisis with the risk of serious consequences, particularly to the kidneys. In such cases, pancreas transplant has been the standard procedure, but recently, due to efforts of the transnational scientific community, pancreatic islet transplantation has progressively been affirmed as a potential alternative procedure and new frontier in the treatment of Type 1 diabetes.
http://www.sacbee.com/2011/10/24/4003270/new-frontier-in-the-treatment.html